This article reviews the promises and challenges in developing and validating biomarkers that could help HCPs distinguish DILI from other causes of liver injury and identify the causative drug.

Abstract and Introduction Current Status of DILI Biomarkers Promising Avenues for Discovery of New DILI Biomarkers Next Steps References The lymphocyte transformation test is commercially ...

Biomarkers are often categorized by their intended uses. For example, pharmacodynamic biomarkers, which measure the effects of a drug on a target, include phosphoproteins, which serve as key ...

CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolationduring preclinical drug development. Extends capabilities of industry-leading PhysioMimix DILI assay for ...

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), drug-induced liver injury (DILI) is the leading cause of acute liver failure in the U.S. It is also a leading ...

New biomarkers could improve early detection and monitoring of kidney injury Date: January 6, 2025 Source: Boston Medical Center Summary: Researchers have identified six new biomarkers that could ...

CAMBRIDGE, England, June 10, 2025--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal ...

Measuring the levels of three biomarkers in blood in midlife may give women a clearer picture of their risk of major cardiovascular events like heart attacks and strokes decades earlier than ...

Researchers say they’ve identified a set of biomarkers that could make early diagnosis of Lyme disease easier, a possible first step for more effectively treating the estimated 476,000 people ...